Analyst Reco. ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
9.71 ^USD	+2.00%		+26.60%	+5.54%

15/04	ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	MT
15/04	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	27/03	MT
HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	21/03	MT
Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	12/03	MT
Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	01/03	MT
Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	26/02	MT
HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	13/12	MT
Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	12/12	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	26/23/26	MT
JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	24/23/24	MT
Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	23/23/23	MT
Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	22/23/22	MT
Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	16/23/16	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	15/23/15	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	10/23/10	MT
Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	05/23/05	MT
HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16	23/23/23	MT
Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15	21/23/21	MT
JPMorgan Adjusts Price Target on ORIC Pharmaceuticals to $15 From $16, Maintains Overweight Rating	21/23/21	MT
Oppenheimer Upgrades ORIC Pharmaceuticals to Outperform From Perform, $14 Price Target	16/23/16	MT
Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $9 from $10, Keeps Buy Rating	20/22/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Analyst Reco.

Filters